BCL11B Upregulates the Expression of NF-κB in T Cells Stimulated with SEA

Yuhui Yan,Senlin Wang,Chen Lin

DOI: https://doi.org/10.21203/rs.3.rs-717701/v1

2021-01-01

Abstract:Abstract BackgroundNF-κB is one of the most important inflammatory mediators in the tumour microenvironment promotes inflammation-induced cancer. Many studies report that NF-κB is activated in many kinds of leukaemia, so that some researchers by inhibiting NF-κB to treat leukaemia. The overexpression of BCL11B has been primarily reported in T cell malignancies. Some studies have reported that BCL11B is a potential transcriptional repressor which has several splice isoforms. MiR-21-5p promotes cell proliferation by targeting BCL11B in Thp-1 human monocytes. Both NF-κB and BCL11B transcription factors are related to inflammation and leukaemia. Whether there is correlation between NF-κB and BCL11B transcription factors? If BCL11B is a potential important transcription factor in treatment of T lymphocyte leukaemia? In this study, we stimulated Jurkat cells and normal peripheral blood T cells with staphylococcal enterotoxin A(SEA), and we detected the expression of both the BCL11B and NF-κB genes and their respective proteins at different stimulation times. Then, the BCL11B gene was suppressed by BCL11B-siRNA and detected at another stimulation time. ResultsWe found that the mRNA expression of BCL11B and NF-κB increased in two kinds of T cell lines over time which stimulated by SEA or PMA+IO. A similar result was confirmed for BCL11B and NF-κB protein expression. While the expression of the NF-κB protein did not increase on equal conditions in the BCL11B-knockdown group. ConclusionOur result suggested that the gene and protein expression levels of both BCL11B and NF-κB were related, and BCL11B regulates NF-κB expression in Jukat cells and healthy human peripheral blood through the TCR signalling pathway. This study reveals that BCL11B can be used as a new therapeutic target for chronic inflammation and T cell leukaemia pathogenesis.